Research Analysts Offer Predictions for KYMR Q3 Earnings

Key Points

• Leerink Partners estimates Kymera Therapeutics will report Q3 2026 EPS of ($1.09), with a full-year estimate of ($2.79) per share.
• Kymera Therapeutics' stock recently saw a 5.4% increase, with a market capitalization of $2.59 billion and a current stock price of $39.71.
• The company's recent earnings report showed a loss of ($0.95) EPS, falling short of consensus estimates by ($0.12), alongside a significant 55.1% year-over-year decline in revenue.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Investment analysts at Leerink Partnrs issued their Q3 2026 EPS estimates for Kymera Therapeutics in a report issued on Monday, August 11th. Leerink Partnrs analyst F. Khurshid forecasts that the company will post earnings per share of ($1.09) for the quarter. The consensus estimate for Kymera Therapeutics' current full-year earnings is ($2.79) per share. Leerink Partnrs also issued estimates for Kymera Therapeutics' Q4 2026 earnings at ($1.11) EPS.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its earnings results on Monday, August 11th. The company reported ($0.95) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.12). The company had revenue of $11.48 million for the quarter, compared to analysts' expectations of $17.37 million. Kymera Therapeutics had a negative return on equity of 31.60% and a negative net margin of 616.03%. The business's revenue was down 55.1% compared to the same quarter last year. During the same period last year, the business posted ($0.58) earnings per share.

A number of other research firms also recently issued reports on KYMR. The Goldman Sachs Group upgraded shares of Kymera Therapeutics to a "strong-buy" rating in a research note on Tuesday, July 15th. JPMorgan Chase & Co. increased their price objective on shares of Kymera Therapeutics from $57.00 to $64.00 and gave the company an "overweight" rating in a research note on Tuesday, June 3rd. B. Riley upgraded shares of Kymera Therapeutics to a "strong-buy" rating and set a $60.00 price objective on the stock in a research note on Wednesday, July 30th. Stifel Nicolaus assumed coverage on shares of Kymera Therapeutics in a research note on Tuesday, May 20th. They set a "buy" rating and a $55.00 price objective on the stock. Finally, Bank of America upgraded shares of Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $51.00 price objective on the stock in a research note on Monday, June 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating, sixteen have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Kymera Therapeutics has an average rating of "Buy" and a consensus price target of $59.11.

Kymera Therapeutics Price Performance

Shares of NASDAQ:KYMR traded up $0.99 during trading on Wednesday, reaching $43.62. 665,521 shares of the company were exchanged, compared to its average volume of 749,805. The firm has a market capitalization of $3.12 billion, a PE ratio of -12.57 and a beta of 2.18. The business's fifty day simple moving average is $44.64 and its 200-day simple moving average is $36.44. Kymera Therapeutics has a 12-month low of $19.44 and a 12-month high of $53.27.

Insider Buying and Selling at Kymera Therapeutics

In other news, Director Elena Ridloff sold 12,000 shares of Kymera Therapeutics stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $46.10, for a total transaction of $553,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bvf Partners L. P/Il acquired 317,167 shares of the stock in a transaction dated Monday, June 30th. The shares were bought at an average price of $44.00 per share, with a total value of $13,955,348.00. Following the completion of the purchase, the director directly owned 2,798,795 shares of the company's stock, valued at approximately $123,146,980. This trade represents a 12.78% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 48,349 shares of company stock valued at $2,334,301. Company insiders own 16.01% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Farther Finance Advisors LLC raised its holdings in shares of Kymera Therapeutics by 642.9% during the second quarter. Farther Finance Advisors LLC now owns 624 shares of the company's stock worth $27,000 after purchasing an additional 540 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Kymera Therapeutics by 506.6% during the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company's stock worth $40,000 after purchasing an additional 770 shares during the last quarter. State of Wyoming purchased a new position in shares of Kymera Therapeutics during the fourth quarter worth $45,000. GF Fund Management CO. LTD. purchased a new position in shares of Kymera Therapeutics during the fourth quarter worth $55,000. Finally, KBC Group NV raised its holdings in shares of Kymera Therapeutics by 15.2% during the first quarter. KBC Group NV now owns 2,479 shares of the company's stock worth $68,000 after purchasing an additional 328 shares during the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.